Quale sarebbe il prezzo per Odyssey Therapeutics, Inc. (ODTX)

Il prezzo per Odyssey Therapeutics, Inc. (ODTX) è $24.55

Qual è la capitalizzazione di mercato per Odyssey Therapeutics, Inc. (ODTX)

La capitalizzazione di mercato per Odyssey Therapeutics, Inc. (ODTX) è $1.18B

Odyssey Therapeutics, Inc. (ODTX) EPS

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Anno	EPS	Cambia
Non abbastanza dati per le date fornite.

Anno

EPS

Cambia

Non abbastanza dati per le date fornite.

Azienda	EPS	Differenza di EPS	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

Azienda

EPS

Differenza di EPS

Il paese